Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
Please note that the ANZCTR website will be unavailable from 9am until 12:30pm (AEDT) on Tuesday 17th November for website maintenance.
Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT05763576
Registration number
NCT05763576
Ethics application status
Date submitted
28/02/2023
Date registered
10/03/2023
Date last updated
22/01/2026
Titles & IDs
Public title
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection
Query!
Scientific title
A Phase I Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection
Query!
Additional trial identifiers [1]
0
0
EU Trial Number
Query!
Additional trial identifiers [2]
0
0
BP44118
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Related trial records
Query!
Health condition
Health condition(s) studied:
Chronic Hepatitis B
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of the intervention or exposure
Treatment: Drugs - RO7565020
Other interventions - Placebo
Treatment: Drugs - Nucleos(t)ide analogue (NUC) treatment
Experimental: RO7565020 -
Placebo comparator: Placebo -
Treatment: Drugs: RO7565020
RO7565020 will be administered by subcutaneous injection or intravenous infusion.
Other interventions: Placebo
Matching placebo will be administered by subcutaneous injection or intravenous infusion.
Treatment: Drugs: Nucleos(t)ide analogue (NUC) treatment
NUC treatment, including tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), or entecavir (ETV), will be administered orally per local prescribing information.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Other interventions
Query!
Description of the comparator or control
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Part 1a: Number of Healthy Volunteers With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [1]
0
0
An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory finding), symptoms, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any significant hazard, contraindication, or side effect that is fatal or life-threatening, requires hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is medically significant or requires intervention.
Query!
Timepoint [1]
0
0
Up to approximately 40 weeks
Query!
Primary outcome [2]
0
0
Part 2a: Number of CHB Participants With AEs and SAEs
Query!
Assessment method [2]
0
0
An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory finding), symptoms, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any significant hazard, contraindication, or side effect that is fatal or life-threatening, requires hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is medically significant or requires intervention.
Query!
Timepoint [2]
0
0
Up to approximately 32 weeks
Query!
Primary outcome [3]
0
0
Part 1a: Number of Healthy Volunteers With Adverse Events of Special Interest (AESI)
Query!
Assessment method [3]
0
0
An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory finding), symptoms, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AESI includes elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value in combination with either an elevated bilirubin value or clinical jaundice and suspected transmission of an infectious agent by the study treatment.
Query!
Timepoint [3]
0
0
Up to approximately 40 weeks
Query!
Primary outcome [4]
0
0
Part 2a: Number of CHB Participants With AESI
Query!
Assessment method [4]
0
0
An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory finding), symptoms, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AESI includes elevated ALT or AST value in combination with either an elevated bilirubin value or clinical jaundice and suspected transmission of an infectious agent by the study treatment.
Query!
Timepoint [4]
0
0
Up to approximately 32 weeks
Query!
Secondary outcome [1]
0
0
Part 1a (SC Cohorts) and Part 2a: Time to Maximum Concentration (Tmax) of RO7565020
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Part 1a: Predose, 1, 4, and 8 hours post-dose on Day 1; Days 2, 3, 4, 8, 15, 21, 29, 57, 85, 141, 197, and 253. Part 2a: Predose, 1, 4, and 8 hours post-dose on Day 1; Days 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, and 169
Query!
Secondary outcome [2]
0
0
Part 1a (IV Cohorts): Tmax of RO7565020
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Predose, 0.08, 1, 4, and 8 hours post-dose on Day 1; Days 2, 3, 4, 8, 15, 21, 29, 57, 85, 141, 197, and 253
Query!
Secondary outcome [3]
0
0
Parts 1a and 2a: Maximum Serum Concentration (Cmax) of RO7565020
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Both Part 1a & 2a Cohorts: Predose, 1, 4, 8 hours post-dose on Day 1; Days 2, 3, 4, 8, 15, 29, 57, 85, & 141. Additionally, Part 1a: Days 21, 197, & 253; Part 2a: Days 22, 113, & 169; IV Cohorts: 0.08 hours after start of infusion, Days 21, 197, & 253
Query!
Secondary outcome [4]
0
0
Parts 1a and 2a: Area Under the Time-concentration Curve From Time 0 to Time of Last Sampling Point or Last Quantifiable Sample, Whichever Comes First (AUC0-last) of RO7565020
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Both Part 1a & 2a Cohorts: Predose, 1, 4, 8 hours post-dose on Day 1; Days 2, 3, 4, 8, 15, 29, 57, 85, & 141. Additionally, Part 1a: Days 21, 197, & 253; Part 2a: Days 22, 113, & 169; IV Cohorts: 0.08 hours after start of infusion, Days 21, 197, & 253
Query!
Secondary outcome [5]
0
0
Parts 1a and 2a: Area Under the Time-concentration Curve From Time 0 to Infinity (AUC0-inf) of RO7565020
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Both Part 1a & 2a Cohorts: Predose, 1, 4, 8 hours post-dose on Day 1; Days 2, 3, 4, 8, 15, 29, 57, 85, & 141. Additionally, Part 1a: Days 21, 197, & 253; Part 2a: Days 22, 113, & 169; IV Cohorts: 0.08 hours after start of infusion, Days 21, 197, & 253
Query!
Secondary outcome [6]
0
0
Parts 1a and 2a: Terminal Half-life (t1/2) of RO7565020
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Both Part 1a & 2a Cohorts: Predose, 1, 4, 8 hours post-dose on Day 1; Days 2, 3, 4, 8, 15, 29, 57, 85, & 141. Additionally, Part 1a: Days 21, 197, & 253; Part 2a: Days 22, 113, & 169; IV Cohorts: 0.08 hours after start of infusion, Days 21, 197, & 253
Query!
Secondary outcome [7]
0
0
Part 1a (IV Cohorts): Volume of Distribution (Vss) of RO7565020
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Predose, 0.08, 1, 4, and 8 hours post-dose on Day 1; Days 2, 3, 4, 8, 15, 21, 29, 57, 85, 141, 197 and 253
Query!
Secondary outcome [8]
0
0
Part 1a (IV Cohorts): Clearance (CL) of RO7565020
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
Predose, 0.08, 1, 4, and 8 hours post-dose on Day 1; Days 2, 3, 4, 8, 15, 21, 29, 57, 85, 141, 197 and 253
Query!
Secondary outcome [9]
0
0
Part 1a (SC Cohorts) and Part 2a: Apparent Clearance (CL/F) of RO7565020
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
Part 1a: Predose, 1, 4, and 8 hours post-dose on Day 1; Days 2, 3, 4, 8, 15, 21, 29, 57, 85, 141, 197, and 253. Part 2a: Predose, 1, 4, and 8 hours post-dose on Day 1; Days 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, and 169
Query!
Secondary outcome [10]
0
0
Part 1a (SC Cohorts) and Part 2a: Apparent Volume of Distribution (Vz/F) at Terminal Phase of RO7565020
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
Part 1a: Predose, 1, 4, and 8 hours post-dose on Day 1; Days 2, 3, 4, 8, 15, 21, 29, 57, 85, 141, 197, and 253. Part 2a: Predose, 1, 4, and 8 hours post-dose on Day 1; Days 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, and 169
Query!
Secondary outcome [11]
0
0
Part 2a: Change From Baseline in Serum Quantitative Hepatitis B Surface Antigen (HBsAg)
Query!
Assessment method [11]
0
0
IU/mL= international units per milliliter
Query!
Timepoint [11]
0
0
Baseline, 4- and 8-hours post-dose on Day 1; subsequently on Days 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, and 169
Query!
Secondary outcome [12]
0
0
Part 2a: Maximum Reduction From Baseline in Serum HBsAg
Query!
Assessment method [12]
0
0
Query!
Timepoint [12]
0
0
Up to Day 169
Query!
Secondary outcome [13]
0
0
Part 2a: Percentage of Participants With HBsAg Loss
Query!
Assessment method [13]
0
0
Query!
Timepoint [13]
0
0
Up to Day 169
Query!
Secondary outcome [14]
0
0
Part 2a: Percentage of Participants With HBsAg Seroconversion
Query!
Assessment method [14]
0
0
HBsAg seroconversion was defined as sustained loss of HBsAg and detection of anti-HBs antibody.
Query!
Timepoint [14]
0
0
Up to Day 169
Query!
Secondary outcome [15]
0
0
Part 2a: Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss Among HBeAg-positive Participants at Baseline
Query!
Assessment method [15]
0
0
Query!
Timepoint [15]
0
0
At Days 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, and 169
Query!
Secondary outcome [16]
0
0
Part 2a: Percentage of Participants With HBeAg Seroconversion Among HBeAg-positive Participants at Baseline
Query!
Assessment method [16]
0
0
HBeAg seroconversion was defined as sustained loss of HBeAg and detection of anti-HBe antibody.
Query!
Timepoint [16]
0
0
Up to Day 169
Query!
Secondary outcome [17]
0
0
Number of Participants With Anti-Drug Antibodies (ADAs) to RO7565020
Query!
Assessment method [17]
0
0
The number of ADA-positive participants at baseline (baseline prevalence) and after drug administration was determined in participants exposed to RO7565020 (post-baseline). Participants were considered ADA positive if they had ADA negative or have missing data at baseline but develop an ADA response following study treatment administration (treatment-induced ADA response), or if they are ADA positive at baseline and the titer of one or more post-baseline samples is at least 4-fold (e.g., = 0.60-titer units) greater than the titer of the baseline sample (treatment enhanced ADA response).
Query!
Timepoint [17]
0
0
Part 1a: Baseline and post-baseline (up to approximately 40 weeks); Part 2a: Baseline and post-baseline (up to approximately 32 weeks)
Query!
Eligibility
Key inclusion criteria
Healthy volunteers:
* Healthy participants
* Body mass index (BMI) between 18 and 32 kg/m^2
CHB participants:
* CHB infection (HBsAg-positive for >/= 6 months)
* On NUC (ETV, TAF, or TDF) monotherapy for >/= 12 months
* Liver biopsy, FibroScan, or equivalent test within the past 6 months demonstrating liver disease consistent with chronic HBV infection without evidence of bridging fibrosis or cirrhosis
* BMI between 18 and 32 kg/m^2
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Healthy volunteers
Yes
Query!
Key exclusion criteria
Healthy volunteers:
* History of any clinically significant disease
* Concomitant disease that could interfere with treatment or conduct of study
* Use of any treatment within the 2 weeks or within 5 half-lives prior to first dosing (whichever is longer)
CHB participants:
* Evidence of liver cirrhosis or decompensated liver disease
* History or suspicion of hepatocellular carcinoma (HCC)
* History or evidence of a medical condition associated with chronic liver disease other than HBV infection, or clinically significant and not adequately controlled non-hepatic disease
* History of or currently receiving any systemic anti-neoplastic or immune-modulatory treatment within the 8 weeks prior to the first dosing or the expectation that such treatment will be needed at any time during the study.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
28/04/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
23/12/2024
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
60
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
Hong Kong
Query!
State/province [2]
0
0
Hong Kong
Query!
Country [3]
0
0
Hong Kong
Query!
State/province [3]
0
0
Shatin, New Territories
Query!
Country [4]
0
0
New Zealand
Query!
State/province [4]
0
0
Auckland
Query!
Country [5]
0
0
South Korea
Query!
State/province [5]
0
0
Chuncheon
Query!
Country [6]
0
0
Spain
Query!
State/province [6]
0
0
Pontevedra
Query!
Country [7]
0
0
Taiwan
Query!
State/province [7]
0
0
Taoyuan
Query!
Country [8]
0
0
Thailand
Query!
State/province [8]
0
0
Bangkok
Query!
Country [9]
0
0
Thailand
Query!
State/province [9]
0
0
Chiang Mai
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a first in human (FIH), multi-center, dose-finding, and dose-escalation Phase I clinical study of RO7565020 to investigate the safety and tolerability and to characterize the pharmacokinetics and pharmacodynamics following single and/or multiple doses of RO7565020 in healthy participants and/or virologically suppressed participants with chronic hepatitis B (CHB).
Query!
Trial website
https://clinicaltrials.gov/study/NCT05763576
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Reference Study ID Number: BP44118 https://forpatients.roche.com/
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
888-662-6728 (U.S. Only)
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
Study Protocol and Statistical Analysis Plan
https://cdn.clinicaltrials.gov/large-docs/76/NCT05763576/Prot_SAP_000.pdf
Statistical analysis plan
Study Protocol and Statistical Analysis Plan
https://cdn.clinicaltrials.gov/large-docs/76/NCT05763576/Prot_SAP_000.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT05763576
Download to PDF